APVO
APVO clinical trials: Aptevo Therapeutics Inc.
Every trial on ClinicalTrials.gov where Aptevo Therapeutics Inc. is the lead sponsor or a listed collaborator, the trials it leads first, each labelled Lead or Collaborator. Phase, status and dates as registered.
- 10
- Trials linked
- 10
- As lead sponsor
- 0
- As collaborator
- 0
- Primary completions as lead sponsor, next 90 days
APVO on the catalyst calendar · APVO registry changes
- Primary completion Oct 2027Sponsor estimatePhase 1NCT06634394APVO436 Phase 1b/2 Study in Patients With Newly Diagnosed AMLAptevo Therapeutics · Acute Myeloid Leukemia (AML)RecruitingAPVOLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Jan 1, 2024Sponsor estimatePhase 1/Phase 2NCT05934539ALG.APV-527 First-in-human StudyAptevo Therapeutics · Solid TumorUnknown statusAPVOLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Dec 15, 2022Sponsor estimatePhase 1NCT03647800Study of APVO436 in Patients With AML or MDSAptevo Research and Development LLC · AMLUnknown statusAPVOLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Jan 2026Sponsor estimatePhase 1NCT04973618Study of APVO436 in Elderly or Unfit Patients With Newly Diagnosed AMLAptevo Therapeutics · AMLWithdrawnAPVOLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Dec 2014ActualPhase 1/Phase 2NCT01188681Safety and Efficacy Study of TRU-016 Plus Bendamustine vs. Bendamustine in Relapsed Chronic Lymphocytic LeukemiaAptevo Therapeutics · Chronic Lymphocytic Leukemia (CLL)CompletedAPVOLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Feb 24, 2020ActualPhase 1NCT01644253Phase 1b Safety and Efficacy Study of TRU-016Aptevo Therapeutics · Chronic Lymphocytic LeukemiaTerminatedAPVOLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Jun 30, 2020ActualPhase 1NCT03768219Study to Evaluate APVO210 in Healthy Subjects, Patients With Psoriasis, and Patients With Ulcerative ColitisAptevo Therapeutics · PsoriasisTerminatedAPVOLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Dec 2018ActualPhase 1NCT02262910Study of ES414 in Metastatic Castration-Resistant Prostate CancerAptevo Therapeutics · Prostate CancerCompletedAPVOLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Apr 2013ActualPhase 1NCT01317901A Study of TRU-016 in Combination With Rituximab and Bendamustine in Subjects With Relapsed Indolent LymphomaAptevo Therapeutics · B-cell Small Lymphocytic Lymphoma RecurrentCompletedAPVOLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Dec 2011ActualPhase 1NCT00614042Phase 1/1b Study of TRU-016 in Patients With Previously Treated CLL or Select Subtypes of Non-Hodgkin's LymphomaAptevo Therapeutics · Chronic Lymphocytic Leukemia (CLL)CompletedAPVOLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
Enrollment, interventions and the start and completion dates are locked on 10 rows here. Included with TrialScanner ($9.99 a month) and Signal8 Pro.
Unlock with TrialScanner